IMS Health RX
-
French drugs market to shrink in 2012 - study
PARIS, March 29 (Reuters) - France's drugs market is set to shrink in 2012 for the first time, hit by government austerity measures to curb healthcare spending, according to a study published by pharmaceutical intelligence firm IMS Health .
-
Vertex Pharmaceuticals ([[VRTX]] -8.1%) gets hit after data from IMS Health shows flat sales in September and the first week of October for the company's hepatitis C drug Incivek.
Vertex Pharmaceuticals ( VRTX -8.1% ) gets hit after data from IMS Health shows flat sales in September and the first week of October for the company's hepatitis C drug Incivek. Post your comment!
-
UPDATE 1-IMS revises Incivek drug data; Vertex shares jump
Oct. 13 (Reuters) - IMS Health , which provides prescription data and other services to the pharmaceutical industry, said it is revising estimates of the number …
-
Generic Drugs Continue To Challenge Big Pharma
… decade. It commissioned an independent study, which was conducted by the IMS Institute for Healthcare Informatics and IMS Health . The report will no doubt get attention on Capital Hil and the GPhA is already calling on the budget "Super Committee …
-
PPD Names New CEO
… Raymond H. Hill joined PPD as chief executive officer and a member of the board last week. He previously was president of IMS Health 's Consulting Group, which is a leading health-care industry consultant. Hill's experience as a consultant in …
-
Drug spending slows: IMS
NEW YORK (Reuters) - Spending growth on prescription drugs slowed to 2.3 percent in 2010 -- the second lowest level in 55 years, according to a report by IMS Health .
-
Asian Emerging Markets Will Grow On You
… intensifying, but we are maintaining our drug-distribution growth forecasts until we see solid evidence to the contrary. IMS Health RX reported February prescription growth of 1.2%, down from 1.4% in January, and lowered its 2003 and 2004 growth …
-
Our Take on the Fourth Quarter
… leader with a nearly 20% gain. A wide range of software firms led the sector to strong gains in the quarter, including IMS Health RX (+38%), Wipro WIT (+25%), and Salesforce.com CRM (+30). The market is betting that improved corporate …
-
20 High-Quality, Cheap Stocks for Last-Minute Shoppers
… didn't match the market's returns. Still, 12 constituents posted positive returns during their three-month run. IMS Health RX led the group with a 33.2% return between Sept. 21 and Dec. 18. In early November, IMS agreed to be acquired …
-
Increasing IMS Health's Uncertainty
While we remain upbeat about the long-term prospects for IMS Health RX, we are increasing our uncertainty rating for the company to high from medium in light of the recent legislative initiatives …